WT1 and Wilms tumor: As a result, all the 15 DSRCTs (100%) demonstrated strong WT1 (C-19) nuclear immunoreactivity, while 71% of the Wilms tumors showed WT1 positivity nuclei, and only 2 out of 17 rhabdomyosarcomas demonstrated rare and focal nuclear positivity for WT1.